Cargando…

Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition

BACKGROUND: Unlike some adult cancers, most pediatric cancers are considered immunologically cold and generally less responsive to immunotherapy. While immunotherapy has already been incorporated into standard of care treatment for pediatric patients with high-risk neuroblastoma, overall survival re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voeller, Julie, Erbe, Amy K., Slowinski, Jacob, Rasmussen, Kayla, Carlson, Peter M., Hoefges, Anna, VandenHeuvel, Sabrina, Stuckwisch, Ashley, Wang, Xing, Gillies, Stephen D., Patel, Ravi B., Farrel, Alvin, Rokita, Jo Lynne, Maris, John, Hank, Jacquelyn A., Morris, Zachary S., Rakhmilevich, Alexander L., Sondel, Paul M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898936/ https://www.ncbi.nlm.nih.gov/pubmed/31810498 http://dx.doi.org/10.1186/s40425-019-0823-6

Ejemplares similares

Cyclophosphamide augments the efficacy of in situ vaccination in a mouse melanoma model
por: Tsarovsky, Noah, et al.
Publicado: (2023)

Depth of tumor implantation affects response to in situ vaccination in a syngeneic murine melanoma model
por: Carlson, Peter M, et al.
Publicado: (2021)

Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma
por: Aiken, Taylor J, et al.
Publicado: (2022)

In vivo synergy of radiation and hu14.18-IL2 immunocytokine results in a memory T cell response in a syngeneic murine melanoma model
por: Morris, Zachary S, et al.
Publicado: (2014)

Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model
por: Baniel, Claire C, et al.
Publicado: (2020)

Short-course neoadjuvant in situ vaccination for murine melanoma
por: Aiken, Taylor J, et al.
Publicado: (2022)

Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma
por: Goldberg, Jacob L, et al.
Publicado: (2020)

In situ Vaccine Plus Checkpoint Blockade Induces Memory Humoral Response
por: Baniel, Claire C., et al.
Publicado: (2020)

Roles of CD4+ T cells as mediators of antitumor immunity
por: Kravtsov, Dmitriy S., et al.
Publicado: (2022)

Increasing the Clinical Efficacy of NK and Antibody-Mediated Cancer Immunotherapy: Potential Predictors of Successful Clinical Outcome Based on Observations in High-Risk Neuroblastoma
por: Koehn, Tony A., et al.
Publicado: (2012)

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
por: Wang, Wei, et al.
Publicado: (2015)

Ranking Antibody Binding Epitopes and Proteins Across Samples from Whole Proteome Tiled Linear Peptides
por: McIlwain, Sean J., et al.
Publicado: (2023)

Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models
por: Pieper, Alexander A., et al.
Publicado: (2021)

Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice
por: Pieper, Alexander A, et al.
Publicado: (2021)

Single cell metabolic imaging of tumor and immune cells in vivo in melanoma bearing mice
por: Heaton, Alexa R., et al.
Publicado: (2023)

Generation of Novel Immunocompetent Mouse Cell Lines to Model Experimental Metastasis of High-Risk Neuroblastoma
por: Dhamdhere, Mayura R., et al.
Publicado: (2023)

Immunocytokine augments local and abscopal response and animal survival when added to radiation and CTLA-4 checkpoint inhibition in a murine melanoma model
por: Morris, Zachary S, et al.
Publicado: (2015)

Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12
por: Barker, S E, et al.
Publicado: (2007)

Computationally efficient mechanism discovery for cell invasion with uncertainty quantification
por: VandenHeuvel, Daniel J., et al.
Publicado: (2022)

Activation of innate and adaptive immunity as an effective combined strategy for cancer immunotherapy
por: Rakhmilevich, Alexander, et al.
Publicado: (2015)

Immunotherapy of Neuroblastoma: Facts and Hopes
por: Anderson, John, et al.
Publicado: (2022)

Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy
por: Hoefges, A, et al.
Publicado: (2023)

Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5- fluorouracil chemotherapy in the B16 melanoma model
por: Rakhmilevich, Alexander, et al.
Publicado: (2013)

The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine
por: O’Connell, Cailin, et al.
Publicado: (2022)

Epigenomic profiling of neuroblastoma cell lines
por: Upton, Kristen, et al.
Publicado: (2020)

Evaluation of novel immunocytokines that preferentially target high or intermediate affinity IL-2 receptors
por: Perez Horta, Zulmarie, et al.
Publicado: (2014)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020)

A mutant fibrinogen that is unable to form fibrin can improve renal phenotype in mice with sickle cell anemia
por: Narciso, Marilou G., et al.
Publicado: (2021)

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab
por: Erbe, Amy K., et al.
Publicado: (2019)

Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist
por: Pieper, Alexander A., et al.
Publicado: (2023)

Combining Immunocytokine and Ex Vivo Activated NK Cells as a Platform for Enhancing Graft-Versus-Tumor Effects Against GD2(+) Murine Neuroblastoma
por: Bates, Paul D., et al.
Publicado: (2021)

Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale Immunity
por: Yarmarkovich, Mark, et al.
Publicado: (2020)

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma
por: Rigo, Valentina, et al.
Publicado: (2017)

BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma
por: Randall, Michael P., et al.
Publicado: (2023)

GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies
por: Pascual-Pasto, Guillem, et al.
Publicado: (2022)

Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma
por: Krytska, Kateryna, et al.
Publicado: (2022)

Glomerulonephritis in Youth With Dystrophic Epidermolysis Bullosa
por: Hughley, Erica, et al.
Publicado: (2020)

LIN28B promotes neuroblastoma metastasis and regulates PDZ binding kinase
por: Chen, Dongdong, et al.
Publicado: (2020)

Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma
por: Makvandi, Mehran, et al.
Publicado: (2022)

Current and Potential Uses of Immunocytokines as Cancer Immunotherapy
por: Sondel, Paul M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1je45kc3muighn3u9vj0vvak43